Thiogenesis Therapeutics, Corp.
TTIPF
$0.42
$0.037.69%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -29.88% | -26.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 57.92% | -46.84% | |||
| Operating Income | -57.92% | 46.84% | |||
| Income Before Tax | -59.94% | 47.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -59.94% | 47.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -59.94% | 47.22% | |||
| EBIT | -57.92% | 46.84% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -43.65% | 47.28% | |||
| Normalized Basic EPS | -43.04% | 47.33% | |||
| EPS Diluted | -43.65% | 47.28% | |||
| Normalized Diluted EPS | -43.04% | 47.33% | |||
| Average Basic Shares Outstanding | 11.54% | -0.07% | |||
| Average Diluted Shares Outstanding | 11.54% | -0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||